CAJ | 학술논문

目的了解68例晚期非小细胞肺癌采用单纯VVP方案静脉治疗和复方苦参注射液联合VVP方案治疗的近期疗效、生活质量、毒副反应等.方法随机分为治疗组(复方苦参注射液联合VVP方案组)36例,对照组(单纯VVP方案组)32例,记录观察近期疗效、毒副反应、生活质量变化.结果治疗组总有效率47.22%,止痛总有效率55.6%;对照组总有效率21.88%,止痛总有效率31.25%.两组总有效率差异显著(P＜0.05).治疗组恶心呕吐、口腔炎、转氨酶升高的发生率低于对照组;对照组化疗后与化疗前相比,白细胞下降明显;治疗组化疗前后白细胞下降不明显.治疗组在化疗后Kps评分稍降低,但无明显差异(P＞0.05),而对照组治疗后评分降低,且有明显差异(P＜0.05).结论复方苦参注射液联合化疗治疗晚期非小细胞肺癌明显提高有效率,确能减低药物毒性,提高患者生活质量.
목적료해68례만기비소세포폐암채용단순VVP방안정맥치료화복방고삼주사액연합VVP방안치료적근기료효、생활질량、독부반응등.방법수궤분위치료조(복방고삼주사액연합VVP방안조)36례,대조조(단순VVP방안조)32례,기록관찰근기료효、독부반응、생활질량변화.결과치료조총유효솔47.22%,지통총유효솔55.6%;대조조총유효솔21.88%,지통총유효솔31.25%.량조총유효솔차이현저(P＜0.05).치료조악심구토、구강염、전안매승고적발생솔저우대조조;대조조화료후여화료전상비,백세포하강명현;치료조화료전후백세포하강불명현.치료조재화료후Kps평분초강저,단무명현차이(P＞0.05),이대조조치료후평분강저,차유명현차이(P＜0.05).결론복방고삼주사액연합화료치료만기비소세포폐암명현제고유효솔,학능감저약물독성,제고환자생활질량.
Objective: To investigate the short-term curative effect ,life quality, side-effects and so on of compound matrine injection combined with chemotherapy (VVP), which was applied to treat advanced non-small cellular lung cancer in 68 cases. Methods: 68 patients were divided randomly into treatment group(compound matrine injection combined with VVP, 36 cases ) and control group (VVP, 32 cases). The short-term therapeutic effect, side effects and life quality of all the patients were recorded. Results: The total efficacy in treatment group was 47.22%,the total pain-relieving rate 55.6%. In contrast, The total effective rate of control group was 21.88% and the total pain-relieving rate 31.25%. The total effective rate of two groups is significantly different (P ＜0.05). Nausea, vomit,stomatitis and transaminases increase in treatment group were lower than those of control group. In control group,leukocyte decreased obviously after chemotherapy, wheras not in treatment group. KPS score in treatment group de creased lightly, there was no obvious difference (P ＞0.05). However, KPS score decreaed obviously with significant difference (P ＜0.05). Conclusions: Compound matrine injection in combination with chemotherapy can improve the efficacy and life quality obviously and reduce medical toxicity in treatnent of the advanced non-small cell lung cancer.